**SUPPLEMENTARY TABLE 2**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **NON RCT studies** |  | **Selection** | | | **Comparability** | | | **Exposure** | | | **Total quality score** |
| **First Author** | **Year** | **The case defination is adequate with independent validation** | **Consecutive or obviously representative series of cases** | **Community controls** | **Controls with no hystory of disease (endpoint)** | **Cases and controls with comparable ages** | **Cases and controls with comparability on any other factors** | **Ascertainment of exposure using secure records (eg surgical records) or structured interviews with blinding to case/control statuses** | **Ascertainment of exposure using the same method for cases and controls** | **Ascertainment of exposure with non-response rate for both groups** |  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
| Kardesxler | 2010 |  | \* | \* |  | \* | \* | \* | \* | \* | low |  |
| Mendes Duarte | 2010 |  |  | \* | \* | \* | \* | \* |  | \* | some concerns |  |
| Shimada | 2010 |  |  |  | \* | \* | \* | \* |  |  | high |  |
| Fentog | 2010 | \* | \* |  | \* | \* | \* | \* |  |  | some concerns |  |
| Vilela | 2011 |  |  | \* |  | \* | \* | \* | \* | \* | some concerns |  |
| Umut | 2013 |  |  | \* |  | \* | \* | \* | \* |  | high |  |
| Patil | 2013 | \* | \* | \* |  | \* | \* | \* | \* | \* | low |  |
| Munenaga | 2013 | \* | \* | \* |  | \* | \* | \* |  |  | some concerns |  |
| Arregocés | 2021 | \* | \* |  |  |  |  | \* |  |  | high |  |
| Anwar | 2020 | \* | \* | \* | \* | \* | \* | \* |  |  | low |  |
| Ide | 2003 |  |  | \* | \* | \* | \* | \* | \* | \* | low |  |

**Table 2.** New Ottawa Scale (NOS) for assessing Risk of Bias (RoB) of Cohort and Case-control studies.